Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Other 1

Conditions

Obesity 7Endometrial Neoplasms 5Prostatic Neoplasms 2Overweight 2Endometrial Hyperplasia 2Diabetes Mellitus 2Breast Neoplasms 2Weight Loss 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Opioid-Related Disorders 1Lymphoma, Follicular 1Insulin Resistance 1Hyperplasia 1Colorectal Neoplasms 1

Interventions

Trastuzumab 597Paclitaxel 562Cyclophosphamide 545Docetaxel 479Capecitabine 388Letrozole 350Fulvestrant 311Doxorubicin 285Carboplatin 277Tamoxifen 257Anastrozole 219exemestane 211Epirubicin 210Radiotherapy 197Bevacizumab 189pertuzumab 177Gemcitabine 163Vinorelbine 162pembrolizumab 161Lapatinib 161palbociclib 152Exercise 132Fluorouracil 118Albumin-Bound Paclitaxel 116eribulin 108Magnetic Resonance Spectroscopy 108130-nm albumin-bound paclitaxel 107Everolimus 103Taxes 96Cisplatin 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms × Tirzepatide × Clear all
NCT07257484 2026-03-13

Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

Weill Medical College of Cornell University

Phase 4 Not yet recruiting
30 enrolled
BreastOther

Breast Neoplasms, Obesity

NCT06517212 2026-02-12

TRIM-EBC

Baylor Research Institute

Phase 2 Recruiting
48 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡